{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:27:19Z","timestamp":1783132039846,"version":"3.54.6"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacig.2026.100705","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:05:00Z","timestamp":1776283500000},"page":"100705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-6795","authenticated-orcid":false,"given":"Shuayb","family":"Elkhalifa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad","family":"AlHameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Cerecedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuzakouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2026.100705_bib1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.anai.2024.10.026","article-title":"Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine","volume":"134","author":"Lang","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2026.100705_bib2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1111\/all.13209","article-title":"The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU","volume":"72","author":"Maurer","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2026.100705_bib3","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100705_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alit.2023.05.003","article-title":"Chronic urticaria and the pathogenic role of mast cells","volume":"72","author":"Elieh-Ali-Komi","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.jacig.2026.100705_bib5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2026.100705_bib6","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacig.2026.100705_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100705_bib8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100705_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/bjd\/ljae067","article-title":"Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial","volume":"191","author":"Altrichter","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacig.2026.100705_bib10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100705_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100117","article-title":"Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-Antihistamines in Asia, Middle-East and Africa: results from the AWARE-AMAC study","volume":"13","author":"Chu","year":"2020","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jacig.2026.100705_bib12","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100705_bib13","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","article-title":"Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status","volume":"13","author":"Casale","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jacig.2026.100705_bib14","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2147\/CCID.S470160","article-title":"Omalizumab in chronic spontaneous urticaria: a real-world study on effectiveness, safety and predictors of treatment outcome","volume":"17","author":"Chen","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jacig.2026.100705_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.alit.2022.09.003","article-title":"Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: a post-marketing surveillance study","volume":"72","author":"Hide","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.jacig.2026.100705_bib16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s40001-025-02852-5","article-title":"Chronic urticaria and vitamin D supplementations: a systematic review","volume":"30","author":"Siddiqui","year":"2025","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jacig.2026.100705_bib17","doi-asserted-by":"crossref","unstructured":"Asero R. Severe CSU with low total IgE levels: is the response to omalizumab always delayed or absent [e-pub ahead of print]? Eur Ann Allergy Clin Immunol https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.360. Accessed December 20, 2025.","DOI":"10.23822\/EurAnnACI.1764-1489.360"},{"key":"10.1016\/j.jacig.2026.100705_bib18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2026.100705_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9856843","article-title":"Thyroid autoimmunity and autoimmunity in chronic spontaneous urticaria linked to disease severity, therapeutic response, and time to remission in patients with chronic spontaneous urticaria","volume":"2018","author":"Chanprapaph","year":"2018","journal-title":"Biomed Res Int"},{"issue":"suppl 3","key":"10.1016\/j.jacig.2026.100705_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/09546634.2018.1527988","article-title":"Omalizumab in chronic spontaneous urticaria: steroid sparing effect","volume":"29","author":"Gatta","year":"2018","journal-title":"J Dermatolog Treat"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829326000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:14:22Z","timestamp":1783131262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829326000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2772829326000676"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100705","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2026.100705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100705"}}